Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed diagnosis of a non-myeloid malignancy~* Baseline hemoglobin (Hb) value of \<= 11.0 g/dL unrelated to transfusion~* No Packed Red Blood Cell (PRBC) or platelet transfusions in the 28 days prior to randomization~* Scheduled to receive chemotherapy for a minimum of 12 weeks during the study~* Eastern Cooperative Oncology Group (ECOG) Performance Status 0 - 2~Exclusion Criteria:~* No planned non-palliative radiation during the study~* No current anemia due to factors other than cancer/chemotherapy (eg, iron deficiency or gastrointestinal bleeding)~* No uncontrolled hypertension (defined as systolic pressure \> 180 and/or a diastolic pressure \> 100 mmHg while receiving antihypertension therapy)~* No history of Deep Venous Thrombosis (DVT) or Pulmonary Embolus (PE) within 12 months before study enrollment. Prior superficial thrombophlebitis is not an exclusion criterion~* No history of Cerebrovascular Accident (CVA), Transient Ischemic Attack (TIA), Acute Coronary Syndrome (ACS) including unstable angina and myocardial infarction with or without ST elevation, or other arterial thrombosis within 6 months before study enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- epoetin alfa (120,000 Units) (Type: EXPERIMENTAL): epoetin alfa (PROCRIT) 120,000 Units injected subcutaneously once every 3 weeks for up to 13 weeks
- epoetin alfa (80,000 Units) (Type: EXPERIMENTAL): epoetin alfa (PROCRIT) 80,000 Units injected subcutaneously once every 3 weeks for up to 13 weeks
- darbepoetin alfa (500 mcg) (Type: ACTIVE_COMPARATOR): darbepoetin alfa (ARANESP) 500 mcg injected subcutaneously the skin once every 3 weeks for up to 13 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).